Biosimilar infliximab for the management of rheumatoid arthritis in France: What are the expected savings?

European Journal of Hospital Pharmacy

Volumn 24, Issue 2, 2017, Pages 85-90

  Beck, M ^a   Michel, B ^a,b   Rybarczyk Vigouret, M C ^a   Sordet, C ^b   Sibilia, J ^b   Velten, M ^c  

^a Agence Régionale de Santé d Alsace   (France)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^c UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

biosimilar; cost; France; infliximab; real life setting; rheumatoid arthritis

Indexed keywords

ADALIMUMAB; BIOSIMILAR AGENT; INFLIXIMAB;

ARTICLE; ECONOMIC DEVELOPMENT; FRANCE; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HOSPITALIZATION COST; HUMAN; OBSERVATIONAL STUDY; PATIENT CARE; RHEUMATOID ARTHRITIS;

EID: 85014568473     PISSN: 20479956     EISSN: 20479964     Source Type: Journal    
DOI: 10.1136/ejhpharm-2016-000904     Document Type: Article

References (30)

1. Singh JA, Furst DE, Bharat A, et al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis: 2012 ACR RA Treatment Recommendations. Arthritis Care Res 2012;64:625-39.
2. Gaujoux-Viala C, Gossec L, Cantagrel A, et al. Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis. Joint Bone Spine 2014;81:287-97.
3. Ramiro S, Gaujoux-Viala C, Nam JL, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014;73:529-35.
4. Nam JL, Ramiro S, Gaujoux-Viala C, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2014;73:516-28.
5. Schoels M, Wong J, Scott DL, et al. Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:995-1003.
6. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
7. Michaud K, Messer J, Choi HK, et al. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum 2003;48:2750-62.
8. Ruof J, Hülsemann JL, Mittendorf T, et al. Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer's data sources. Ann Rheum Dis 2003;62:544-9.
9. Juillard-Condat B, Constantin A, Cambon-Thomsen A, et al. Impact of etanercept on the costs of rheumatoid arthritis (RA): results from a French observational study. Joint Bone Spine 2008;75:25-8.
10. Kalkan A, Hallert E, Bernfort L, et al. Costs of rheumatoid arthritis during the period 1990-2010: a register-based cost-of-illness study in Sweden. Rheumatol Oxf Engl 2014;53:153-60.
11. Weise M, Bielsky M-C, De Smet K, et al. Biosimilars: what clinicians should know. Blood 2012;120:5111-17.
12. European Medicines Agency (EMA). Guideline on similar biological medicinal products. 2014. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2014/10/WC500176768.pdf (accessed 21 Apr 2015).
13. European Medicines Agency (EMA). Guideline on similar biological medicinal products containing monoclonal antibodies-non-clinical and clinical issues. 2012. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/06/WC500128686.pdf (accessed 29 Oct 2015).
14. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013;72:1613-20.
15. Baji P, Péntek M, Czirják L, et al. Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison. Eur J Health Econ HEPAC Health Econ Prev Care 2014;15(Suppl 1): S53-64.
16. Isaacs JD, Cutolo M, Keystone EC, et al. Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody. J Intern Med 2016;279:41-59.
17. Gulácsi L, Brodszky V, Baji P, et al. Biosimilars for the management of rheumatoid arthritis: economic considerations. Expert Rev Clin Immunol 2015;11(Suppl 1):43-52.
18. Haustein R, de Millas C, Höer A, et al. Saving money in the European healthcare systems with biosimilars. Generics Biosimilars Initiat J 2012;1:120-6.
19. Brodszky V, Baji P, Balogh O, et al. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. Eur J Health Econ HEPAC Health Econ Prev Care 2014;15(Suppl 1):S65-71.
20. Jha A, Upton A, Dunlop WC, et al. The budget impact of biosimilar infliximab (Remsima®) for the treatment of autoimmune diseases in five European countries. Adv Ther 2015;32:742-56.
21. McCarthy G, Ebel Bitoun C, Guy H. Introduction of an infliximab biosimilar (CT-P13): a five-year budget impact analysis for the treatment of rheumatoid arthritis in Ireland. Value Health 2013;16:A558.
22. Lucioni C, Mazzi S, Caporali R. Budget impact analysis of infliximab biosimilar: the Italian scenery. Glob Reg Health Technol Assess 2015;2:78-88.
23. Kim J, Hong J, Kudrin A. 5 Year budget impact analysis of biosimilar infliximab for the treatment of rheumatoid arthritis in UK, Italy, France and Germany. Arthritis Rheumatol 2014;11:S512 (abstract 1166).
24. Beck M, Velten M, Rybarczyk-Vigouret M-C, et al. Analysis and breakdown of overall 1-year costs relative to inpatient and outpatient care among rheumatoid arthritis patients treated with biotherapies using health insurance claims database in Alsace. Drugs-Real World Outcomes 2015;2:205-15.
25. Assurance maladie (Ameli). ALD 30 en 2012-incidence. http://www.ameli.fr/l-Assurance-maladie/statistiques-et-publications/donnees-statistiques/affection-de-longue-duree-Ald/incidence/ald-30-en-2012.php (accessed 29 Oct 2015).
26. Institut national de la statistique et des études économiques (Insee). Données détaillées de la situation démographique en 2013. http://www.insee.fr/fr/themes/detail.asp?ref-id=ir-irsocsd2013&page=irweb/irsocsd2013/dd/irsocsd2013-population.htm (accessed 29 Oct 2015).
27. European Commission. What you need to know about biosimilar medicinal products -A consensus information document. 2013. http://ec.europa.eu/DocsRoom/documents/8242/attachments/1/translations/en/renditions/native (accessed 30 Oct 2015).
28. Henry D, Taylor C. Pharmacoeconomics of cancer therapies: considerations with the introduction of biosimilars. Semin Oncol 2014;41(Suppl 3):S13-20.
29. Polimeni G, Trifiró G, Ingrasciotta Y, et al. The advent of biosimilars for the treatment of diabetes: current status and future directions. Acta Diabetol 2015;52:423-31.
30. DeVries JH, Gough SCL, Kiljanski J, et al. Biosimilar insulins: a European perspective. Diabetes Obes Metab 2015;17:445-51.